Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer
Abstract
1. Introduction
2. ROS Impacts Cancer Metabolic Reprogramming
2.1. Direct Regulation through Key Metabolic Enzymes
2.1.1. Glycolysis
2.1.2. TCA Cycle
2.2. Indirect Regulation through Oncogene or Tumor Suppressor Networks
2.2.1. AMP-Activated Protein Kinase (AMPK)
2.2.2. Hypoxia-Inducible Factor 1 (HIF-1)
2.2.3. p53
2.2.4. ROS-Responsive miRNAs
3. Glucose Metabolic Adaptation Alters the Redox Balance
3.1. Glycolysis
3.2. Pentose Phosphate Pathway
3.3. Tri-Carboxylic Acid (TCA) Cycle
4. Metabolic Deregulations Lead to Drug Resistance
4.1. Glycolysis
4.2. Pentose Phosphate Pathway
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Warburg, O.; Wind, F.; Negelein, E. The Metabolism of Tumors in the Body. J. Gen. Physiol. 1927, 8, 519–530. [Google Scholar] [CrossRef] [PubMed]
- Gillies, R.J.; Gatenby, R.A. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J. Bioenerg. Biomembr. 2007, 39, 251–257. [Google Scholar] [CrossRef] [PubMed]
- Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23, 27–47. [Google Scholar] [CrossRef] [PubMed]
- Nakashima, R.A.; Paggi, M.G.; Pedersen, P.L. Contributions of glycolysis and oxidative phosphorylation to adenosine 5′-triphosphate production in AS-30D hepatoma cells. Cancer Res. 1984, 44, 5702–5706. [Google Scholar]
- Pfeiffer, T.; Schuster, S.; Bonhoeffer, S. Cooperation and competition in the evolution of ATP-producing pathways. Science 2001, 292, 504–507. [Google Scholar] [CrossRef]
- Papathanassiou, D.; Bruna-Muraille, C.; Jouannaud, C.; Gagneux-Lemoussu, L.; Eschard, J.P.; Liehn, J.C. Single-photon emission computed tomography combined with computed tomography (SPECT/CT) in bone diseases. Joint Bone Spine 2009, 76, 474–480. [Google Scholar] [CrossRef]
- Sowers, M.L.; Herring, J.; Zhang, W.; Tang, H.; Ou, Y.; Gu, W.; Zhang, K. Analysis of glucose-derived amino acids involved in one-carbon and cancer metabolism by stable-isotope tracing gas chromatography mass spectrometry. Anal. Biochem. 2019, 566, 1–9. [Google Scholar] [CrossRef]
- Madhu, B.; Jauhiainen, A.; McGuire, S.; Griffiths, J.R. Exploration of human brain tumour metabolism using pairwise metabolite-metabolite correlation analysis (MMCA) of HR-MAS 1H NMR spectra. PLoS ONE 2017, 12, e0185980. [Google Scholar] [CrossRef]
- Cortes-Cros, M.; Hemmerlin, C.; Ferretti, S.; Zhang, J.; Gounarides, J.S.; Yin, H.; Muller, A.; Haberkorn, A.; Chene, P.; Sellers, W.R.; et al. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc. Natl. Acad. Sci. USA 2013, 110, 489–494. [Google Scholar] [CrossRef] [PubMed]
- Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 2004, 101, 3329–3335. [Google Scholar] [CrossRef] [PubMed]
- Lum, J.J.; Bauer, D.E.; Kong, M.; Harris, M.H.; Li, C.; Lindsten, T.; Thompson, C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120, 237–248. [Google Scholar] [CrossRef] [PubMed]
- Ganapathy-Kanniappan, S.; Kunjithapatham, R.; Geschwind, J.F. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res. 2013, 33, 13–20. [Google Scholar] [PubMed]
- Samudio, I.; Fiegl, M.; Andreeff, M. Mitochondrial uncoupling and the Warburg effect: Molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 2009, 69, 2163–2166. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y.; Zhang, X.; Zhang, H.; Lan, J.; Huang, G.; Varin, E.; Lincet, H.; Poulain, L.; Icard, P. Citrate induces apoptotic cell death: A promising way to treat gastric carcinoma? Anticancer Res. 2011, 31, 797–805. [Google Scholar]
- Lincet, H.; Kafara, P.; Giffard, F.; Abeilard-Lemoisson, E.; Duval, M.; Louis, M.H.; Poulain, L.; Icard, P. Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells. J. Ovarian Res. 2013, 6, 72. [Google Scholar] [CrossRef]
- Kruspig, B.; Nilchian, A.; Orrenius, S.; Zhivotovsky, B.; Gogvadze, V. Citrate kills tumor cells through activation of apical caspases. Cell Mol. Life Sci. 2012, 69, 4229–4237. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef]
- D’Autreaux, B.; Toledano, M.B. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 2007, 8, 813–824. [Google Scholar] [CrossRef]
- Maraini, G.; Gozzoli, F. Binding of retinol to isolated retinal pigment epithelium in the presence and absence of retinol-binding protein. Investig. Ophthalmol. 1975, 14, 785–787. [Google Scholar] [CrossRef]
- Keenan, M.M.; Chi, J.T. Alternative fuels for cancer cells. Cancer J. 2015, 21, 49–55. [Google Scholar] [CrossRef]
- Galluzzi, L.; Kepp, O.; Vander Heiden, M.G.; Kroemer, G. Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 2013, 12, 829–846. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Kim, J.; Bae, J.S. ROS homeostasis and metabolism: a critical liaison for cancer therapy. Exp. Mol. Med. 2016, 48, e269. [Google Scholar] [CrossRef] [PubMed]
- Ma, L.; Fu, Q.; Xu, B.; Zhou, H.; Gao, J.; Shao, X.; Xiong, J.; Gu, Q.; Wen, S.; Li, F.; et al. Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation. Int. J. Cancer 2018, 142, 1786–1796. [Google Scholar] [CrossRef] [PubMed]
- Juarez, J.C.; Manuia, M.; Burnett, M.E.; Betancourt, O.; Boivin, B.; Shaw, D.E.; Tonks, N.K.; Mazar, A.P.; Donate, F. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc. Natl. Acad. Sci. USA 2008, 105, 7147–7152. [Google Scholar] [CrossRef]
- Anastasiou, D.; Poulogiannis, G.; Asara, J.M.; Boxer, M.B.; Jiang, J.K.; Shen, M.; Bellinger, G.; Sasaki, A.T.; Locasale, J.W.; Auld, D.S.; et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334, 1278–1283. [Google Scholar] [CrossRef]
- Wellen, K.E.; Thompson, C.B. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol. Cell 2010, 40, 323–332. [Google Scholar] [CrossRef]
- Lu, W.; Hu, Y.; Chen, G.; Chen, Z.; Zhang, H.; Wang, F.; Feng, L.; Pelicano, H.; Wang, H.; Keating, M.J.; et al. Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLoS Biol. 2017, 15, e1002616. [Google Scholar] [CrossRef]
- Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87, 245–313. [Google Scholar] [CrossRef]
- Jurica, M.S.; Mesecar, A.; Heath, P.J.; Shi, W.; Nowak, T.; Stoddard, B.L. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 1998, 6, 195–210. [Google Scholar] [CrossRef]
- Anastasiou, D.; Yu, Y.; Israelsen, W.J.; Jiang, J.K.; Boxer, M.B.; Hong, B.S.; Tempel, W.; Dimov, S.; Shen, M.; Jha, A.; et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 2012, 8, 839–847. [Google Scholar] [CrossRef]
- Christofk, H.R.; Vander Heiden, M.G.; Harris, M.H.; Ramanathan, A.; Gerszten, R.E.; Wei, R.; Fleming, M.D.; Schreiber, S.L.; Cantley, L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452, 230–233. [Google Scholar] [CrossRef] [PubMed]
- Luo, W.; Semenza, G.L. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol. Metab. 2012, 23, 560–566. [Google Scholar] [CrossRef] [PubMed]
- Bluemlein, K.; Gruning, N.M.; Feichtinger, R.G.; Lehrach, H.; Kofler, B.; Ralser, M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011, 2, 393–400. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Liu, X.; Yin, Y.; Zheng, J.T.; Jiang, C.F.; Wang, J.; Shen, H.; Li, C.Y.; Wang, M.; Liu, L.Z.; et al. Insulin regulates glucose consumption and lactate production through reactive oxygen species and pyruvate kinase M2. Oxid. Med. Cell. Longev. 2014, 2014, 504953. [Google Scholar] [CrossRef] [PubMed]
- Iqbal, M.A.; Siddiqui, F.A.; Gupta, V.; Chattopadhyay, S.; Gopinath, P.; Kumar, B.; Manvati, S.; Chaman, N.; Bamezai, R.N. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol. Cancer 2013, 12, 72. [Google Scholar] [CrossRef]
- Maddocks, O.D.; Vousden, K.H. Metabolic regulation by p53. J. Mol. Med. (Berl.) 2011, 89, 237–245. [Google Scholar] [CrossRef]
- Ralser, M.; Wamelink, M.M.; Kowald, A.; Gerisch, B.; Heeren, G.; Struys, E.A.; Klipp, E.; Jakobs, C.; Breitenbach, M.; Lehrach, H.; et al. Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress. J. Biol. 2007, 6, 10. [Google Scholar] [CrossRef]
- Nguewa, P.A.; Agorreta, J.; Blanco, D.; Lozano, M.D.; Gomez-Roman, J.; Sanchez, B.A.; Valles, I.; Pajares, M.J.; Pio, R.; Rodriguez, M.J.; et al. Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol. Biol. 2008, 9, 103. [Google Scholar] [CrossRef]
- Jung, M.; Ramankulov, A.; Roigas, J.; Johannsen, M.; Ringsdorf, M.; Kristiansen, G.; Jung, K. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol. Biol. 2007, 8, 47. [Google Scholar] [CrossRef]
- Rubie, C.; Kempf, K.; Hans, J.; Su, T.; Tilton, B.; Georg, T.; Brittner, B.; Ludwig, B.; Schilling, M. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol. Cell. Probes 2005, 19, 101–109. [Google Scholar] [CrossRef]
- McKenzie, S.J.; Baker, M.S.; Buffinton, G.D.; Doe, W.F. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Investig. 1996, 98, 136–141. [Google Scholar] [CrossRef] [PubMed]
- McKenzie, S.M.; Doe, W.F.; Buffinton, G.D. 5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells. Gut 1999, 44, 180–185. [Google Scholar] [CrossRef] [PubMed]
- Sukhanov, S.; Higashi, Y.; Shai, S.Y.; Itabe, H.; Ono, K.; Parthasarathy, S.; Delafontaine, P. Novel effect of oxidized low-density lipoprotein: cellular ATP depletion via downregulation of glyceraldehyde-3-phosphate dehydrogenase. Circ. Res. 2006, 99, 191–200. [Google Scholar] [CrossRef] [PubMed]
- Hwang, N.R.; Yim, S.H.; Kim, Y.M.; Jeong, J.; Song, E.J.; Lee, Y.; Lee, J.H.; Choi, S.; Lee, K.J. Oxidative modifications of glyceraldehyde-3-phosphate dehydrogenase play a key role in its multiple cellular functions. Biochem. J. 2009, 423, 253–264. [Google Scholar] [CrossRef] [PubMed]
- Rodacka, A.; Strumillo, J.; Serafin, E.; Puchala, M. Effect of resveratrol and tiron on the inactivation of glyceraldehyde-3- phosphate dehydrogenase induced by superoxide anion radical. Curr. Med. Chem. 2014, 21, 1061–1069. [Google Scholar] [CrossRef] [PubMed]
- Ishii, T.; Sunami, O.; Nakajima, H.; Nishio, H.; Takeuchi, T.; Hata, F. Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide. Biochem. Pharmacol. 1999, 58, 133–143. [Google Scholar] [CrossRef]
- Uetaki, M.; Tabata, S.; Nakasuka, F.; Soga, T.; Tomita, M. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci. Rep. 2015, 5, 13896. [Google Scholar] [CrossRef]
- Wang, P.; Mai, C.; Wei, Y.L.; Zhao, J.J.; Hu, Y.M.; Zeng, Z.L.; Yang, J.; Lu, W.H.; Xu, R.H.; Huang, P. Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med. Oncol. 2013, 30, 552. [Google Scholar] [CrossRef]
- Ternette, N.; Yang, M.; Laroyia, M.; Kitagawa, M.; O’Flaherty, L.; Wolhulter, K.; Igarashi, K.; Saito, K.; Kato, K.; Fischer, R.; et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 2013, 3, 689–700. [Google Scholar] [CrossRef]
- Singh, K.K.; Desouki, M.M.; Franklin, R.B.; Costello, L.C. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol. Cancer 2006, 5, 14. [Google Scholar] [CrossRef]
- Han, D.; Canali, R.; Garcia, J.; Aguilera, R.; Gallaher, T.K.; Cadenas, E. Sites and mechanisms of aconitase inactivation by peroxynitrite: modulation by citrate and glutathione. Biochemistry 2005, 44, 11986–11996. [Google Scholar] [CrossRef] [PubMed]
- Castro, L.; Rodriguez, M.; Radi, R. Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J. Biol. Chem. 1994, 269, 29409–29415. [Google Scholar] [PubMed]
- Cantu, D.; Schaack, J.; Patel, M. Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS ONE 2009, 4, e7095. [Google Scholar] [CrossRef] [PubMed]
- Ciccarone, F.; Di Leo, L.; Lazzarino, G.; Maulucci, G.; Di Giacinto, F.; Tavazzi, B.; Ciriolo, M.R. Aconitase 2 inhibits the proliferation of MCF-7 cells promoting mitochondrial oxidative metabolism and ROS/FoxO1-mediated autophagic response. Br. J. Cancer 2020, 122, 182–193. [Google Scholar] [CrossRef]
- Applegate, M.A.; Humphries, K.M.; Szweda, L.I. Reversible inhibition of alpha-ketoglutarate dehydrogenase by hydrogen peroxide: Glutathionylation and protection of lipoic acid. Biochemistry 2008, 47, 473–478. [Google Scholar] [CrossRef]
- Humphries, K.M.; Yoo, Y.; Szweda, L.I. Inhibition of NADH-linked mitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry 1998, 37, 552–557. [Google Scholar] [CrossRef]
- Metallo, C.M.; Gameiro, P.A.; Bell, E.L.; Mattaini, K.R.; Yang, J.; Hiller, K.; Jewell, C.M.; Johnson, Z.R.; Irvine, D.J.; Guarente, L.; et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011, 481, 380–384. [Google Scholar] [CrossRef]
- Mullen, A.R.; Wheaton, W.W.; Jin, E.S.; Chen, P.H.; Sullivan, L.B.; Cheng, T.; Yang, Y.; Linehan, W.M.; Chandel, N.S.; DeBerardinis, R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2011, 481, 385–388. [Google Scholar] [CrossRef]
- Nitsch, L.; Garbi, C.; Gentile, R.; Mascia, A.; Negri, R.; Polistina, C.; Vergani, G.; Zurzolo, C. Morphological changes induced by prolonged TSH stimulation or starvation in the rat thyroid cell line FRTL. Horm. Metab. Res. Suppl. 1990, 23, 32–37. [Google Scholar]
- Sun, R.C.; Denko, N.C. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014, 19, 285–292. [Google Scholar] [CrossRef]
- Levine, A.J.; Puzio-Kuter, A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330, 1340–1344. [Google Scholar] [CrossRef] [PubMed]
- Faubert, B.; Boily, G.; Izreig, S.; Griss, T.; Samborska, B.; Dong, Z.; Dupuy, F.; Chambers, C.; Fuerth, B.J.; Viollet, B.; et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013, 17, 113–124. [Google Scholar] [CrossRef] [PubMed]
- Vara-Ciruelos, D.; Russell, F.M.; Hardie, D.G. The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde? (dagger). Open Biol. 2019, 9, 190099. [Google Scholar] [CrossRef] [PubMed]
- Cairns, R.A.; Harris, I.S.; Mak, T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11, 85–95. [Google Scholar] [CrossRef]
- Jeon, S.M.; Chandel, N.S.; Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485, 661–665. [Google Scholar] [CrossRef]
- Zmijewski, J.W.; Banerjee, S.; Bae, H.; Friggeri, A.; Lazarowski, E.R.; Abraham, E. Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. J. Biol. Chem. 2010, 285, 33154–33164. [Google Scholar] [CrossRef]
- Li, L.; Chen, Y.; Gibson, S.B. Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation. Cell. Signal. 2013, 25, 50–65. [Google Scholar] [CrossRef]
- Hinchy, E.C.; Gruszczyk, A.V.; Willows, R.; Navaratnam, N.; Hall, A.R.; Bates, G.; Bright, T.P.; Krieg, T.; Carling, D.; Murphy, M.P. Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly. J. Biol. Chem. 2018, 293, 17208–17217. [Google Scholar] [CrossRef]
- Gordan, J.D.; Simon, M.C. Hypoxia-inducible factors: Central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 2007, 17, 71–77. [Google Scholar] [CrossRef]
- Vaupel, P.; Harrison, L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9 (Suppl. S5), 4–9. [Google Scholar] [CrossRef]
- Ghanbari Movahed, Z.; Rastegari-Pouyani, M.; Mohammadi, M.H.; Mansouri, K. Cancer cells change their glucose metabolism to overcome increased ROS: One step from cancer cell to cancer stem cell? Biomed. Pharmacother. 2019, 112, 108690. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177–185. [Google Scholar] [CrossRef] [PubMed]
- Lu, C.W.; Lin, S.C.; Chen, K.F.; Lai, Y.Y.; Tsai, S.J. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J. Biol. Chem. 2008, 283, 28106–28114. [Google Scholar] [CrossRef] [PubMed]
- Tello, D.; Balsa, E.; Acosta-Iborra, B.; Fuertes-Yebra, E.; Elorza, A.; Ordonez, A.; Corral-Escariz, M.; Soro, I.; Lopez-Bernardo, E.; Perales-Clemente, E.; et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha decreases oxygen consumption by inhibiting Complex I activity. Cell Metab. 2011, 14, 768–779. [Google Scholar] [CrossRef] [PubMed]
- Zhao, T.; Zhu, Y.; Morinibu, A.; Kobayashi, M.; Shinomiya, K.; Itasaka, S.; Yoshimura, M.; Guo, G.; Hiraoka, M.; Harada, H. HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Sci. Rep. 2014, 4, 3793. [Google Scholar] [CrossRef] [PubMed]
- Xia, C.; Meng, Q.; Liu, L.Z.; Rojanasakul, Y.; Wang, X.R.; Jiang, B.H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 2007, 67, 10823–10830. [Google Scholar] [CrossRef]
- Gao, N.; Shen, L.; Zhang, Z.; Leonard, S.S.; He, H.; Zhang, X.G.; Shi, X.; Jiang, B.H. Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol. Cell. Biochem. 2004, 255, 33–45. [Google Scholar] [CrossRef]
- Zhou, Q.; Liu, L.Z.; Fu, B.; Hu, X.; Shi, X.; Fang, J.; Jiang, B.H. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007, 28, 28–37. [Google Scholar] [CrossRef]
- Liu, B.; Chen, Y.; St Clair, D.K. ROS and p53: A versatile partnership. Free Radic. Biol. Med. 2008, 44, 1529–1535. [Google Scholar] [CrossRef]
- Wu, G.S. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol. Ther. 2004, 3, 156–161. [Google Scholar] [CrossRef]
- Iorio, M.V.; Croce, C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2017, 9, 852. [Google Scholar] [CrossRef] [PubMed]
- Jin, L.H.; Wei, C. Role of microRNAs in the Warburg effect and mitochondrial metabolism in cancer. Asian Pac. J. Cancer Prev. 2014, 15, 7015–7019. [Google Scholar] [CrossRef] [PubMed]
- He, J.; Jiang, B.H. Interplay between Reactive oxygen Species and MicroRNAs in Cancer. Curr. Pharmacol. Rep. 2016, 2, 82–90. [Google Scholar] [CrossRef]
- Kim, H.R.; Roe, J.S.; Lee, J.E.; Cho, E.J.; Youn, H.D. p53 regulates glucose metabolism by miR-34a. Biochem. Biophys. Res. Commun. 2013, 437, 225–231. [Google Scholar] [CrossRef] [PubMed]
- Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12, 931–947. [Google Scholar] [CrossRef] [PubMed]
- Vafa, O.; Wade, M.; Kern, S.; Beeche, M.; Pandita, T.K.; Hampton, G.M.; Wahl, G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell 2002, 9, 1031–1044. [Google Scholar] [CrossRef]
- Sullivan, L.B.; Chandel, N.S. Mitochondrial reactive oxygen species and cancer. Cancer Metab 2014, 2, 17. [Google Scholar] [CrossRef]
- Goldman, R.D.; Kaplan, N.O.; Hall, T.C. Lactic Dehydrogenase in Human Neoplastic Tissues. Cancer Res. 1964, 24, 389–399. [Google Scholar]
- Le, A.; Cooper, C.R.; Gouw, A.M.; Dinavahi, R.; Maitra, A.; Deck, L.M.; Royer, R.E.; Vander Jagt, D.L.; Semenza, G.L.; Dang, C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 2037–2042. [Google Scholar] [CrossRef]
- Arseneault, R.; Chien, A.; Newington, J.T.; Rappon, T.; Harris, R.; Cumming, R.C. Attenuation of LDHA expression in cancer cells leads to redox-dependent alterations in cytoskeletal structure and cell migration. Cancer Lett. 2013, 338, 255–266. [Google Scholar] [CrossRef]
- Frederiks, W.M.; Vizan, P.; Bosch, K.S.; Vreeling-Sindelarova, H.; Boren, J.; Cascante, M. Elevated activity of the oxidative and non-oxidative pentose phosphate pathway in (pre)neoplastic lesions in rat liver. Int. J. Exp. Pathol. 2008, 89, 232–240. [Google Scholar] [CrossRef] [PubMed]
- Bannasch, P.; Benner, U.; Hacker, H.J.; Klimek, F.; Mayer, D.; Moore, M.; Zerban, H. Cytochemical and biochemical microanalysis of carcinogenesis. Histochem. J. 1981, 13, 799–820. [Google Scholar] [CrossRef]
- Van Driel, B.E.; De Goeij, A.F.; Song, J.Y.; De Bruine, A.P.; Van Noorden, C.J. Development of oxygen insensitivity of the quantitative histochemical assay of G6PDH activity during colorectal carcinogenesis. J. Pathol. 1997, 182, 398–403. [Google Scholar] [CrossRef]
- Van Noorden, C.J.; Bahns, S.; Kohler, A. Adaptational changes in kinetic parameters of G6PDH but not of PGDH during contamination-induced carcinogenesis in livers of North Sea flatfish. Biochim. Biophys. Acta 1997, 1342, 141–148. [Google Scholar] [CrossRef]
- Ju, H.Q.; Lu, Y.X.; Wu, Q.N.; Liu, J.; Zeng, Z.L.; Mo, H.Y.; Chen, Y.; Tian, T.; Wang, Y.; Kang, T.B.; et al. Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene 2017, 36, 6282–6292. [Google Scholar] [CrossRef] [PubMed]
- Tian, W.N.; Braunstein, L.D.; Pang, J.; Stuhlmeier, K.M.; Xi, Q.C.; Tian, X.; Stanton, R.C. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J. Biol. Chem. 1998, 273, 10609–10617. [Google Scholar] [CrossRef] [PubMed]
- Kuo, W.; Lin, J.; Tang, T.K. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int. J. Cancer 2000, 85, 857–864. [Google Scholar] [CrossRef]
- Ruwende, C.; Hill, A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J. Mol. Med. (Berl.) 1998, 76, 581–588. [Google Scholar] [CrossRef]
- Zhang, Z.; Liew, C.W.; Handy, D.E.; Zhang, Y.; Leopold, J.A.; Hu, J.; Guo, L.; Kulkarni, R.N.; Loscalzo, J.; Stanton, R.C. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J. 2010, 24, 1497–1505. [Google Scholar] [CrossRef]
- Leopold, J.A.; Walker, J.; Scribner, A.W.; Voetsch, B.; Zhang, Y.Y.; Loscalzo, A.J.; Stanton, R.C.; Loscalzo, J. Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J. Biol. Chem. 2003, 278, 32100–32106. [Google Scholar] [CrossRef]
- Leopold, J.A.; Zhang, Y.Y.; Scribner, A.W.; Stanton, R.C.; Loscalzo, J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 411–417. [Google Scholar] [CrossRef] [PubMed]
- Boveris, A.; Cadenas, E.; Stoppani, A.O. Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. Biochem. J. 1976, 156, 435–444. [Google Scholar] [CrossRef] [PubMed]
- Turrens, J.F.; Alexandre, A.; Lehninger, A.L. Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria. Arch Biochem. Biophys. 1985, 237, 408–414. [Google Scholar] [CrossRef]
- Fleury, C.; Mignotte, B.; Vayssiere, J.L. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002, 84, 131–141. [Google Scholar] [CrossRef]
- Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am. J. Physiol. 1996, 271, C1424–C1437. [Google Scholar] [CrossRef] [PubMed]
- Radi, R.; Cassina, A.; Hodara, R.; Quijano, C.; Castro, L. Peroxynitrite reactions and formation in mitochondria. Free Radic. Biol. Med. 2002, 33, 1451–1464. [Google Scholar] [CrossRef]
- Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82, 47–95. [Google Scholar] [CrossRef]
- Stadtman, E.R.; Levine, R.L. Protein oxidation. Ann. N. Y. Acad. Sci. 2000, 899, 191–208. [Google Scholar] [CrossRef]
- Rubbo, H.; Radi, R.; Trujillo, M.; Telleri, R.; Kalyanaraman, B.; Barnes, S.; Kirk, M.; Freeman, B.A. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J. Biol. Chem. 1994, 269, 26066–26075. [Google Scholar]
- Schulz, T.J.; Thierbach, R.; Voigt, A.; Drewes, G.; Mietzner, B.; Steinberg, P.; Pfeiffer, A.F.; Ristow, M. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J. Biol. Chem. 2006, 281, 977–981. [Google Scholar] [CrossRef]
- Gross, M.I.; Demo, S.D.; Dennison, J.B.; Chen, L.; Chernov-Rogan, T.; Goyal, B.; Janes, J.R.; Laidig, G.J.; Lewis, E.R.; Li, J.; et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 2014, 13, 890–901. [Google Scholar] [CrossRef] [PubMed]
- Shroff, E.H.; Eberlin, L.S.; Dang, V.M.; Gouw, A.M.; Gabay, M.; Adam, S.J.; Bellovin, D.I.; Tran, P.T.; Philbrick, W.M.; Garcia-Ocana, A.; et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc. Natl. Acad. Sci. USA 2015, 112, 6539–6544. [Google Scholar] [CrossRef] [PubMed]
- Matre, P.; Velez, J.; Jacamo, R.; Qi, Y.; Su, X.; Cai, T.; Chan, S.M.; Lodi, A.; Sweeney, S.R.; Ma, H.; et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget 2016, 7, 79722–79735. [Google Scholar] [CrossRef] [PubMed]
- Wakil, S.J.; Porter, J.W.; Gibson, D.M. Studies on the mechanism of fatty acid synthesis. I. Preparation and purification of an enzymes system for reconstruction of fatty acid synthesis. Biochim. Biophys. Acta 1957, 24, 453–461. [Google Scholar] [CrossRef]
- Geisbrecht, B.V.; Gould, S.J. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J. Biol. Chem. 1999, 274, 30527–30533. [Google Scholar] [CrossRef]
- Wise, D.R.; Ward, P.S.; Shay, J.E.; Cross, J.R.; Gruber, J.J.; Sachdeva, U.M.; Platt, J.M.; DeMatteo, R.G.; Simon, M.C.; Thompson, C.B. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 2011, 108, 19611–19616. [Google Scholar] [CrossRef]
- Stoddard, B.L.; Dean, A.; Koshland, D.E., Jr. Structure of isocitrate dehydrogenase with isocitrate, nicotinamide adenine dinucleotide phosphate, and calcium at 2.5-A resolution: a pseudo-Michaelis ternary complex. Biochemistry 1993, 32, 9310–9316. [Google Scholar] [CrossRef]
- Ramachandran, N.; Colman, R.F. Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase. J. Biol. Chem. 1980, 255, 8859–8864. [Google Scholar]
- Lee, S.H.; Jo, S.H.; Lee, S.M.; Koh, H.J.; Song, H.; Park, J.W.; Lee, W.H.; Huh, T.L. Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays. Int. J. Radiat. Biol. 2004, 80, 635–642. [Google Scholar] [CrossRef]
- Calvert, A.E.; Chalastanis, A.; Wu, Y.; Hurley, L.A.; Kouri, F.M.; Bi, Y.; Kachman, M.; May, J.L.; Bartom, E.; Hua, Y.; et al. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 2017, 19, 1858–1873. [Google Scholar] [CrossRef]
- Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061–1068. [Google Scholar] [CrossRef] [PubMed]
- Zarei, M.; Lal, S.; Parker, S.J.; Nevler, A.; Vaziri-Gohar, A.; Dukleska, K.; Mambelli-Lisboa, N.C.; Moffat, C.; Blanco, F.F.; Chand, S.N.; et al. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Res. 2017, 77, 4460–4471. [Google Scholar] [CrossRef] [PubMed]
- Ma, Q.L.; Wang, J.H.; Wang, Y.G.; Hu, C.; Mu, Q.T.; Yu, M.X.; Wang, L.; Wang, D.M.; Yang, M.; Yin, X.F.; et al. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia. Int. J. Cancer 2015, 137, 1058–1065. [Google Scholar] [CrossRef]
- Beljaards, R.C.; Meijer, C.J.; Scheffer, E.; van der Valk, P.; Willemze, R. Differential diagnosis of cutaneous large cell lymphomas using monoclonal antibodies reactive in paraffin-embedded skin biopsy specimens. Am. J. Dermatopathol. 1991, 13, 342–349. [Google Scholar] [CrossRef] [PubMed]
- Figueroa, M.E.; Abdel-Wahab, O.; Lu, C.; Ward, P.S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H.F.; et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18, 553–567. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Kato, Y.; Kaneko, M.K.; Sugawara, M.; Ogasawara, S.; Tsujimoto, Y.; Naganuma, Y.; Yamakawa, M.; Tsuchiya, T.; Takagi, M. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med. 2013, 2, 803–814. [Google Scholar] [CrossRef]
- Murugan, A.K.; Bojdani, E.; Xing, M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem. Biophys. Res. Commun. 2010, 393, 555–559. [Google Scholar] [CrossRef]
- Shi, J.; Sun, B.; Shi, W.; Zuo, H.; Cui, D.; Ni, L.; Chen, J. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumour Biol. 2015, 36, 655–662. [Google Scholar] [CrossRef]
- Zhao, S.; Lin, Y.; Xu, W.; Jiang, W.; Zha, Z.; Wang, P.; Yu, W.; Li, Z.; Gong, L.; Peng, Y.; et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324, 261–265. [Google Scholar] [CrossRef]
- Losman, J.A.; Looper, R.E.; Koivunen, P.; Lee, S.; Schneider, R.K.; McMahon, C.; Cowley, G.S.; Root, D.E.; Ebert, B.L.; Kaelin, W.G., Jr. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339, 1621–1625. [Google Scholar] [CrossRef]
- Kaminska, B.; Czapski, B.; Guzik, R.; Krol, S.K.; Gielniewski, B. Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins. Molecules 2019, 24, 968. [Google Scholar] [CrossRef] [PubMed]
- Murai, S.; Ando, A.; Ebara, S.; Hirayama, M.; Satomi, Y.; Hara, T. Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions. Oncogenesis 2017, 6, e329. [Google Scholar] [CrossRef] [PubMed]
- Frenkel, R. Regulation and physiological functions of malic enzymes. Curr. Top. Cell. Regul. 1975, 9, 157–181. [Google Scholar] [CrossRef] [PubMed]
- Pongratz, R.L.; Kibbey, R.G.; Shulman, G.I.; Cline, G.W. Cytosolic and mitochondrial malic enzyme isoforms differentially control insulin secretion. J. Biol. Chem. 2007, 282, 200–207. [Google Scholar] [CrossRef] [PubMed]
- Nakashima, C.; Yamamoto, K.; Fujiwara-Tani, R.; Luo, Y.; Matsushima, S.; Fujii, K.; Ohmori, H.; Sasahira, T.; Sasaki, T.; Kitadai, Y.; et al. Expression of cytosolic malic enzyme (ME1) is associated with disease progression in human oral squamous cell carcinoma. Cancer Sci. 2018, 109, 2036–2045. [Google Scholar] [CrossRef]
- Fernandes, L.M.; Al-Dwairi, A.; Simmen, R.C.M.; Marji, M.; Brown, D.M.; Jewell, S.W.; Simmen, F.A. Malic Enzyme 1 (ME1) is pro-oncogenic in Apc(Min/+) mice. Sci. Rep. 2018, 8, 14268. [Google Scholar] [CrossRef]
- Lu, Y.X.; Ju, H.Q.; Liu, Z.X.; Chen, D.L.; Wang, Y.; Zhao, Q.; Wu, Q.N.; Zeng, Z.L.; Qiu, H.B.; Hu, P.S.; et al. ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis. Cancer Res. 2018, 78, 1972–1985. [Google Scholar] [CrossRef]
- Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 2018, 18, 452–464. [Google Scholar] [CrossRef]
- Fletcher, J.I.; Williams, R.T.; Henderson, M.J.; Norris, M.D.; Haber, M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist. Updat. 2016, 26, 1–9. [Google Scholar] [CrossRef]
- Thews, O.; Gassner, B.; Kelleher, D.K.; Schwerdt, G.; Gekle, M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 2006, 8, 143–152. [Google Scholar] [CrossRef]
- Wojtkowiak, J.W.; Verduzco, D.; Schramm, K.J.; Gillies, R.J. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol. Pharm. 2011, 8, 2032–2038. [Google Scholar] [CrossRef] [PubMed]
- Vukovic, V.; Tannock, I.F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 1997, 75, 1167–1172. [Google Scholar] [CrossRef] [PubMed]
- Seebacher, N.A.; Richardson, D.R.; Jansson, P.J. Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics. Br. J. Pharmacol. 2015, 172, 2557–2572. [Google Scholar] [CrossRef] [PubMed]
- Bhatt, A.N.; Chauhan, A.; Khanna, S.; Rai, Y.; Singh, S.; Soni, R.; Kalra, N.; Dwarakanath, B.S. Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells. BMC Cancer 2015, 15, 335. [Google Scholar] [CrossRef]
- Wagner, W.; Ciszewski, W.M.; Kania, K.D. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation. Cell Commun. Signal. 2015, 13, 36. [Google Scholar] [CrossRef]
- Zhao, J.G.; Ren, K.M.; Tang, J. Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism. Tumour Biol. 2014, 35, 12305–12315. [Google Scholar] [CrossRef]
- Ma, S.; Jia, R.; Li, D.; Shen, B. Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells. BioMed Res. Int. 2015, 2015, 453986. [Google Scholar] [CrossRef]
- Wintzell, M.; Lofstedt, L.; Johansson, J.; Pedersen, A.B.; Fuxe, J.; Shoshan, M. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol. Ther. 2012, 13, 1454–1462. [Google Scholar] [CrossRef]
- Sullivan, E.J.; Kurtoglu, M.; Brenneman, R.; Liu, H.; Lampidis, T.J. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother. Pharmacol. 2014, 73, 417–427. [Google Scholar] [CrossRef]
- Zhang, X.Y.; Zhang, M.; Cong, Q.; Zhang, M.X.; Zhang, M.Y.; Lu, Y.Y.; Xu, C.J. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Int. J. Biochem. Cell Biol. 2018, 95, 9–16. [Google Scholar] [CrossRef]
- Vartanian, A.; Agnihotri, S.; Wilson, M.R.; Burrell, K.E.; Tonge, P.D.; Alamsahebpour, A.; Jalali, S.; Taccone, M.S.; Mansouri, S.; Golbourn, B.; et al. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget 2016, 7, 69518–69535. [Google Scholar] [CrossRef] [PubMed]
- Fan, K.; Fan, Z.; Cheng, H.; Huang, Q.; Yang, C.; Jin, K.; Luo, G.; Yu, X.; Liu, C. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Cancer Med. 2019, 8, 5903–5915. [Google Scholar] [CrossRef] [PubMed]
- Jiang, J.X.; Gao, S.; Pan, Y.Z.; Yu, C.; Sun, C.Y. Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol. Med. Rep. 2014, 10, 995–1002. [Google Scholar] [CrossRef] [PubMed]
- Li, W.C.; Huang, C.H.; Hsieh, Y.T.; Chen, T.Y.; Cheng, L.H.; Chen, C.Y.; Liu, C.J.; Chen, H.M.; Huang, C.L.; Lo, J.F.; et al. Regulatory Role of Hexokinase 2 in Modulating Head and Neck Tumorigenesis. Front. Oncol. 2020, 10, 176. [Google Scholar] [CrossRef]
- Kwon, O.H.; Kang, T.W.; Kim, J.H.; Kim, M.; Noh, S.M.; Song, K.S.; Yoo, H.S.; Kim, W.H.; Xie, Z.; Pocalyko, D.; et al. Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem. Biophys. Res. Commun. 2012, 423, 38–44. [Google Scholar] [CrossRef]
- Martinez-Balibrea, E.; Plasencia, C.; Gines, A.; Martinez-Cardus, A.; Musulen, E.; Aguilera, R.; Manzano, J.L.; Neamati, N.; Abad, A. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol. Cancer Ther. 2009, 8, 771–778. [Google Scholar] [CrossRef]
- Yoo, B.C.; Ku, J.L.; Hong, S.H.; Shin, Y.K.; Park, S.Y.; Kim, H.K.; Park, J.G. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int. J. Cancer 2004, 108, 532–539. [Google Scholar] [CrossRef]
- Wang, Y.; Hao, F.; Nan, Y.; Qu, L.; Na, W.; Jia, C.; Chen, X. PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis. Int. J. Biol. Sci. 2018, 14, 1883–1891. [Google Scholar] [CrossRef]
- Wang, X.; Zhang, F.; Wu, X.R. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Sci. Rep. 2017, 7, 45983. [Google Scholar] [CrossRef]
- Liu, Y.; He, C.; Huang, X. Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism. Oncotarget 2017, 8, 75206–75216. [Google Scholar] [CrossRef]
- Guo, C.Y.; Yan, C.; Luo, L.; Goto, S.; Urata, Y.; Xu, J.J.; Wen, X.M.; Kuang, Y.K.; Tou, F.F.; Li, T.S. Enhanced expression of PKM2 associates with the biological properties of cancer stem cells from A549 human lung cancer cells. Oncol. Rep. 2017, 37, 2161–2166. [Google Scholar] [CrossRef] [PubMed]
- Doi, K.; Onodera, T.; Tsuda, T.; Matsuzaki, H.; Mitsuoka, T. Histopathology of BALB/c mice infected with the D variant of encephalomyocarditis virus. Br. J. Exp. Pathol. 1988, 69, 395–401. [Google Scholar] [PubMed]
- Shin, Y.K.; Yoo, B.C.; Hong, Y.S.; Chang, H.J.; Jung, K.H.; Jeong, S.Y.; Park, J.G. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009, 30, 2182–2192. [Google Scholar] [CrossRef] [PubMed]
- Sirover, M.A. Subcellular dynamics of multifunctional protein regulation: mechanisms of GAPDH intracellular translocation. J. Cell. Biochem. 2012, 113, 2193–2200. [Google Scholar] [CrossRef]
- Butera, G.; Mullappilly, N.; Masetto, F.; Palmieri, M.; Scupoli, M.T.; Pacchiana, R.; Donadelli, M. Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in Cancer and Neurodegenerative Disorders. Int. J. Mol. Sci. 2019, 20, 62. [Google Scholar] [CrossRef]
- Phadke, M.; Krynetskaia, N.; Krynetskiy, E. Cytotoxicity of chemotherapeutic agents in glyceraldehyde-3-phosphate dehydrogenase-depleted human lung carcinoma A549 cells with the accelerated senescence phenotype. Anticancer Drugs 2013, 24, 366–374. [Google Scholar] [CrossRef]
- Phadke, M.S.; Krynetskaia, N.F.; Mishra, A.K.; Krynetskiy, E. Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines. J. Pharmacol. Exp. Ther. 2009, 331, 77–86. [Google Scholar] [CrossRef]
- Dando, I.; Pacchiana, R.; Pozza, E.D.; Cataldo, I.; Bruno, S.; Conti, P.; Cordani, M.; Grimaldi, A.; Butera, G.; Caraglia, M.; et al. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism. Free Radic. Biol. Med. 2017, 113, 176–189. [Google Scholar] [CrossRef]
- Chen, R.W.; Saunders, P.A.; Wei, H.; Li, Z.; Seth, P.; Chuang, D.M. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. J. Neurosci. 1999, 19, 9654–9662. [Google Scholar] [CrossRef]
- Fiucci, G.; Beaucourt, S.; Duflaut, D.; Lespagnol, A.; Stumptner-Cuvelette, P.; Geant, A.; Buchwalter, G.; Tuynder, M.; Susini, L.; Lassalle, J.M.; et al. Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. Proc. Natl. Acad. Sci. USA 2004, 101, 3510–3515. [Google Scholar] [CrossRef]
- Hara, M.R.; Agrawal, N.; Kim, S.F.; Cascio, M.B.; Fujimuro, M.; Ozeki, Y.; Takahashi, M.; Cheah, J.H.; Tankou, S.K.; Hester, L.D.; et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat. Cell Biol. 2005, 7, 665–674. [Google Scholar] [CrossRef] [PubMed]
- Hara, M.R.; Snyder, S.H. Nitric oxide-GAPDH-Siah: a novel cell death cascade. Cell Mol. Neurobiol. 2006, 26, 527–538. [Google Scholar] [CrossRef] [PubMed]
- Thangima Zannat, M.; Bhattacharjee, R.B.; Bag, J. In the absence of cellular poly (A) binding protein, the glycolytic enzyme GAPDH translocated to the cell nucleus and activated the GAPDH mediated apoptotic pathway by enhancing acetylation and serine 46 phosphorylation of p53. Biochem. Biophys. Res. Commun. 2011, 409, 171–176. [Google Scholar] [CrossRef] [PubMed]
- Butera, G.; Pacchiana, R.; Mullappilly, N.; Margiotta, M.; Bruno, S.; Conti, P.; Riganti, C.; Donadelli, M. Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochim. Biophys. Acta Mol. Cell. Res. 2018, 1865, 1914–1923. [Google Scholar] [CrossRef] [PubMed]
- Li, K.; Huang, M.; Xu, P.; Wang, M.; Ye, S.; Wang, Q.; Zeng, S.; Chen, X.; Gao, W.; Chen, J.; et al. Microcystins-LR induced apoptosis via S-nitrosylation of GAPDH in colorectal cancer cells. Ecotoxicol. Environ. Saf. 2020, 190, 110096. [Google Scholar] [CrossRef] [PubMed]
- Tamada, M.; Nagano, O.; Tateyama, S.; Ohmura, M.; Yae, T.; Ishimoto, T.; Sugihara, E.; Onishi, N.; Yamamoto, T.; Yanagawa, H.; et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res. 2012, 72, 1438–1448. [Google Scholar] [CrossRef]
- Lucarelli, G.; Galleggiante, V.; Rutigliano, M.; Sanguedolce, F.; Cagiano, S.; Bufo, P.; Lastilla, G.; Maiorano, E.; Ribatti, D.; Giglio, A.; et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget 2015, 6, 13371–13386. [Google Scholar] [CrossRef]
- Polimeni, M.; Voena, C.; Kopecka, J.; Riganti, C.; Pescarmona, G.; Bosia, A.; Ghigo, D. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem. J. 2011, 439, 141–149. [Google Scholar] [CrossRef]
- Catanzaro, D.; Gaude, E.; Orso, G.; Giordano, C.; Guzzo, G.; Rasola, A.; Ragazzi, E.; Caparrotta, L.; Frezza, C.; Montopoli, M. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget 2015, 6, 30102–30114. [Google Scholar] [CrossRef]
- Hong, W.; Cai, P.; Xu, C.; Cao, D.; Yu, W.; Zhao, Z.; Huang, M.; Jin, J. Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System. Front. Pharmacol. 2018, 9, 43. [Google Scholar] [CrossRef]
- Zhang, R.; Tao, F.; Ruan, S.; Hu, M.; Hu, Y.; Fang, Z.; Mei, L.; Gong, C. The TGFbeta1-FOXM1-HMGA1-TGFbeta1 positive feedback loop increases the cisplatin resistance of non-small cell lung cancer by inducing G6PD expression. Am. J. Transl. Res. 2019, 11, 6860–6876. [Google Scholar] [PubMed]
- Liu, R.; Li, W.; Tao, B.; Wang, X.; Yang, Z.; Zhang, Y.; Wang, C.; Liu, R.; Gao, H.; Liang, J.; et al. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance. Nat. Commun. 2019, 10, 991. [Google Scholar] [CrossRef] [PubMed]
- Ma, L.; Cheng, Q. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Biochem. Biophys. Res. Commun. 2018, 498, 912–917. [Google Scholar] [CrossRef] [PubMed]
- Sarfraz, I.; Rasul, A.; Hussain, G.; Shah, M.A.; Zahoor, A.F.; Asrar, M.; Selamoglu, Z.; Ji, X.Y.; Adem, S.; Sarker, S.D. 6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance. Biofactors 2020. [Google Scholar] [CrossRef]
- Li, Q.; Qin, T.; Bi, Z.; Hong, H.; Ding, L.; Chen, J.; Wu, W.; Lin, X.; Fu, W.; Zheng, F.; et al. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat. Commun. 2020, 11, 1456. [Google Scholar] [CrossRef]
- Shukla, S.K.; Purohit, V.; Mehla, K.; Gunda, V.; Chaika, N.V.; Vernucci, E.; King, R.J.; Abrego, J.; Goode, G.D.; Dasgupta, A.; et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 2017, 32, 71–87. [Google Scholar] [CrossRef]
- Yang, H.; Wu, X.L.; Wu, K.H.; Zhang, R.; Ju, L.L.; Ji, Y.; Zhang, Y.W.; Xue, S.L.; Zhang, Y.X.; Yang, Y.F.; et al. MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. Am. J. Cancer Res. 2016, 6, 2690–2699. [Google Scholar]
- Ko, Y.H.; Verhoeven, H.A.; Lee, M.J.; Corbin, D.J.; Vogl, T.J.; Pedersen, P.L. A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J. Bioenerg. Biomembr. 2012, 44, 163–170. [Google Scholar] [CrossRef]
- Zhang, Q.; Zhang, Y.; Zhang, P.; Chao, Z.; Xia, F.; Jiang, C.; Zhang, X.; Jiang, Z.; Liu, H. Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer 2014, 5, 100–112. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bhardwaj, V.; He, J. Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer. Int. J. Mol. Sci. 2020, 21, 3412. https://doi.org/10.3390/ijms21103412
Bhardwaj V, He J. Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer. International Journal of Molecular Sciences. 2020; 21(10):3412. https://doi.org/10.3390/ijms21103412
Chicago/Turabian StyleBhardwaj, Vikas, and Jun He. 2020. "Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer" International Journal of Molecular Sciences 21, no. 10: 3412. https://doi.org/10.3390/ijms21103412
APA StyleBhardwaj, V., & He, J. (2020). Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer. International Journal of Molecular Sciences, 21(10), 3412. https://doi.org/10.3390/ijms21103412